Antipyretic TRIZ Cases

Replacing mouse framework residues with human sequences reduces immunogenicity while preserving binding affinity for interleukin-20.

A chewable gel composition uses high(methyl)pectin to form a graspable solid without liquid.

Oral cyclic peptides trap interleukin-1 beta to address vascular inflammation in atherosclerosis, complementing cholesterol-lowering therapies.

Alpha-ketoacid compounds react specifically with hydrogen peroxide to enable in vivo imaging via hyperpolarized magnetic resonance.

Acid hydrolysis of oleuropein yields hydroxytyrosol that reduces homocysteine by 7.5-20% and CRP by 50%, addressing inadequate conventional therapy.

Histidyl-tRNA synthetase polypeptides block pathogenic anti-Jo-1 antibodies, reducing disease progression while avoiding side effects from non-specific drugs.

A topical gel combines nimesulide and thiocolchicoside with menthol to enhance percutaneous absorption.

Agonist antibodies bind PD-1 to induce ligand-like signaling, resolving inadequate modulation of PD-1 expression in autoimmune treatments.

Engineered humanized anti-TL1A antibodies reduce deamidation liabilities while maintaining high binding affinity to treat inflammatory bowel disease.

Human monoclonal antibodies target CD19 to treat B-cell malignancies while eliminating the human anti-mouse antibody response.

Optimized zwitterionic coatings reduce non-specific protein absorption while enabling selective cellular uptake for targeted immunotherapy.

A topical liniment combines castor oil with herbal polyphenols to deliver active compounds through the skin barrier.